Investors will likely focus on the sales performance of AbbVie's blockbuster immunology drugs, Rinvoq and Skyrizi, when it ...

Cantor Fitzgerald starts AbbVie with an Overweight rating and $210 target, citing strong drug growth, low risk, and no major ...

Due to the essentiality of healthcare, the medical sector can provide a defensive hedge against market uncertainty, and ...

Not only are pharmaceutical stocks excellent defensive investments, some pharma stocks pay sizable dividends that can be a ...

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

BofA lowered the firm’s price target on AbbVie (ABBV) to $200 from $223 and keeps a Neutral rating on the shares. The firm updated estimates ...

Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Galapagos (Euronext: GLPG) has appointed Henry Gosebruch as chief executive of its upcoming oncology spin-off, marking a ...

But AbbVie planned exceptionally well for this loss of exclusivity. Its two successors to Humira (Rinvoq and Skyrizi) are on track to generate more sales combined than Humira did at its peak. AbbVie ...

Last year, AbbVie’s Skyrizi and Rinvoq were practically unshakeable atop the monthly TV drug ad spending rankings, ultimately leading the pair of immunology meds to take the full-year title for ...